EUCTR2017-000111-16-Outside-EU/EEA进行中（未招募）1 期
Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India. - Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females in India
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •a. Healthy females age 9 to 15 years.
- •b. Must not yet have had coitarche and does not plan on becoming sexually active through the course of the study.
- •c. Must agree to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes.
- •d. No feverish feeling within 24 hours prior to the first injection and no temperature =100°F or =37.8°C (oral or oral equivalent) at first vaccination.
- •e. Not pregnant now (as determined by a serum pregnancy test or urine pregnancy test sensitive to 25 IU HCG).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 110
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Individuals concurrently enrolled in clinical studies of investigational agents or studies involving collection of cervical/genital specimens.
- •b. History of known prior vaccination with an HPV vaccine.
- •c. Subject has received non-replicating (inactivated) vaccine within 14 days prior to the Day 1 vaccination or has received replicating (live virus) vaccine within 21 days prior to the Day 1 vaccination.
- •d. Individuals allergic to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]).
- •e. Individuals who have received any immune globulin preparation or blood derived
- •products within the 6 months prior to the first injection, or plan to receive any through the completion of the study.
- •f. Individuals with a history of splenectomy, known immune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis), or receiving immunosuppressives (e.g., substances or treatments known to diminish immune response such as radiation therapy, administration of antimetabolites, antilymphocytic sera, systemic corticosteroids). Individuals who have received periodic treatments with immunosuppressives, defined as at least 3 courses of systemic corticosteroids each lasting at least 1 week in duration for the year prior to enrollment, will be excluded. Subjects using topical steroids (i.e., inhaled or nasal) will be eligible for vaccination.
- •g. Individuals with known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •h. Any condition which in the opinion of the investigator might interfere with the
- •evaluation of the study objectives.
- •i. Any plans to permanently relocate from the area prior to the completion of the
- •study or to leave for an extended period of time when study visits would need to be scheduled.
- •j. Individuals who are immunocompromised or have been diagnosed as having HIV infection.
- •k. History of recent or ongoing alcohol or other drug abuse.
- •Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and legal problems as a result of alcohol use.
- •l. Inability to give consent/assent.
研究者
相似试验
已完成
1 期
Subcutaneous immunotherapy with PROLINEM -Asthma- Adults-Fase IAsthmaRPCEC00000139ational Center of Bioproducts (BioCen)20
招募中
不适用
Assessment of the safety, tolerance, and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers:KCT0000604Eyegene24
招募中
1 期
A study to Evaluate Immunogenicity, Safety and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2COVID-19 diseaseMedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-005504-36-DKBavarian Nordic A/S4,000
招募中
1 期
Phase ?/? clinical trial of Shifa-Pharmed COVID-19 inactivated vaccine (CovIran-Barkat) among healthy adolescents aged 12 to 18 years.IRCT20171122037571N3SHIFAPHARMED Industrial Group Co500
尚未招募
3 期
Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in HavanaPneumococcal diseasesVCN7-TPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsRPCEC00000432Finlay Vaccine Institute (FVI)